D
Devin Schellenberg
Researcher at University of British Columbia
Publications - 51
Citations - 3883
Devin Schellenberg is an academic researcher from University of British Columbia. The author has contributed to research in topics: Medicine & SABR volatility model. The author has an hindex of 17, co-authored 35 publications receiving 2455 citations. Previous affiliations of Devin Schellenberg include BC Cancer Agency & Stanford University.
Papers
More filters
Journal ArticleDOI
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Gwendolyn H.M.J. Griffioen,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Glenn Bauman,Andrew Warner,Suresh Senan +21 more
TL;DR: SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death.
Journal ArticleDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis and durable over time and there were no new safety signals, and S ABR had no detrimental impact on QOL.
Journal ArticleDOI
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
Daniel T. Chang,Devin Schellenberg,John Shen,Jeff Kim,Karyn A. Goodman,George A. Fisher,James M. Ford,Terry S. Desser,Andrew Quon,Albert C. Koong +9 more
TL;DR: The authors report on the local control and toxicity of stereotactic body radiotherapy (SBRT) for patients with unresectable pancreatic adenocarcinoma.
Journal ArticleDOI
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
Devin Schellenberg,Karyn A. Goodman,Florence Lee,Stephanie T. Chang,Timothy Kuo,James M. Ford,George A. Fisher,Andrew Quon,Terry S. Desser,Jeffrey A. Norton,Ralph S. Greco,George P. Yang,Albert C. Koong +12 more
TL;DR: SBRT with gemcitabine resulted in comparable survival to conventional chemoradiotherapy and good local control, however, the rate of duodenal ulcer development was significant.
Posted ContentDOI
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma,Robert Olson,Stephen Harrow,Stewart Gaede,Alexander V. Louie,Cornelis J.A. Haasbeek,Liam Mulroy,Michael Lock,George Rodrigues,Brian Yaremko,Devin Schellenberg,Belal Ahmad,Sashendra Senthi,Anand Swaminath,Neil Kopek,Mitchell Liu,Karen Moore,S. Currie,Roel Schlijper,Glenn Bauman,Joanna Laba,X. Melody Qu,Andrew Warner,Suresh Senan +23 more
TL;DR: With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time, and there were no new safety signals, and S ABR had no detrimental impact on QOL.